A novel model-based approach for dose determination of glycopyrronium bromide in COPD

Abstract

BACKGROUND Glycopyrronium bromide (NVA237) is an inhaled long-acting muscarinic antagonist in development for treatment of COPD. This study compared the efficacy and safety of once-daily (OD) and twice-daily (BID) glycopyrronium bromide regimens, using a novel model-based approach, in patients with moderate-to-severe COPD. METHODS Double-blind, randomized… (More)
DOI: 10.1186/1471-2466-12-74

Topics

7 Figures and Tables

Slides referencing similar topics